Is serum HMGB1 a biomarker in ANCA-associated vasculitis?

Arthritis Research and Therapy

Volumn 15, Issue 5, 2013, Pages

  de Souza, Alexandre W S ^a,b   Westra, Johanna ^a   Bijzet, Johan ^a   Limburg, Pieter C ^a   Stegeman, Coen A ^a   Bijl, Marc ^c   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c MARTINI HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; ANCA ASSOCIATED VASCULITIS; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; MALE; PROTEIN BLOOD LEVEL; PROTEINURIA; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REMISSION; AGED; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MIDDLE AGED; NEPHRITIS; RISK FACTOR; TIME;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIBODIES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; NEPHRITIS; RECURRENCE; RISK FACTORS; TIME FACTORS;

EID: 84883266411     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4284     Document Type: Article

References (27)

1. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192. 10.1002/art.1780370206, 8129773.
2. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006, 368:404-418. 10.1016/S0140-6736(06)69114-9, 16876669.
3. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005, 143:621-631. 10.7326/0003-4819-143-9-200511010-00005, 16263884.
4. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352:351-361. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.
5. Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006, 45:724-729. 10.1093/rheumatology/kei272, 16399845.
6. Walsh M, Flossmann O, Berden A, Westman K, Hoglund P, Stegeman C, Jayne D. European Vasculitis Study Group Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012, 64:542-548. 10.1002/art.33361, 21953279, European Vasculitis Study Group.
7. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 2012, 7:240-247. 10.2215/CJN.05610611, 3280023, 22134625.
8. Popa ER, Stegeman CA, Abdulahad WH, van der Meer B, Arends J, Manson WM, Bos NA, Kallenberg CG, Tervaert JW. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007, 46:1029-1033. 10.1093/rheumatology/kem022, 17409134.
9. Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis - a meta-analysis. Rheumatology (Oxford) 2012, 51:100-109. 10.1093/rheumatology/ker280, 3276294, 22039267.
10. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012, 8:195-202. 10.1038/nrrheum.2011.222, 22293756.
11. de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012, 11:909-917. 10.1016/j.autrev.2012.03.007, 22495229.
12. Abdulahad DA, Westra J, Bijzet J, Dolff S, van Dijk MC, Limburg PC, Kallenberg CG, Bijl M. Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations. Arthritis Res Ther 2012, 14:R184. 10.1186/ar4015, 3580580, 22892043.
13. Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:R71. 10.1186/ar3332, 3218880, 21548924.
14. Zickert A, Palmblad K, Sundelin B, Chavan S, Tracey KJ, Bruchfeld A, Gunnarsson I. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther 2012, 14:R36. 10.1186/ar3747, 3392835, 22348591.
15. Wibisono D, Csernok E, Lamprecht P, Holle JU, Gross WL, Moosig F. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis. Ann Rheum Dis 2010, 69:1888-1889. 10.1136/ard.2009.119172, 20542962.
16. Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, Palmblad K, Gunnarsson I. High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 2011, 17:29-35. 3022976, 20844833.
17. Henes F, Chen Y, Bley T, Fabel M, Both M, Herrmann K, Csernok E, Gross W, Moosig F. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 2011, 70:1926-1929. 10.1136/ard.2010.146456, 21765168.
18. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007, 66:222-227. 1798520, 16901958.
19. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009, 68:1827-1832. 10.1136/ard.2008.101279, 19054820.
20. Hayashi A, Nagafuchi H, Ito I, Hirota K, Yoshida M, Ozaki S. Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod Rheumatol 2009, 19:283-292. 10.1007/s10165-009-0151-7, 19214652.
21. Barnay-Verdier S, Fattoum L, Borde C, Kaveri S, Gibot S, Marechal V. Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock. Intensive Care Med 2011, 37:957-962. 10.1007/s00134-011-2192-6, 21359606.
22. Sato F, Maruyama S, Hayashi H, Sakamoto I, Yamada S, Uchimura T, Morita Y, Ito Y, Yuzawa Y, Maruyama I, Matsuo S. High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract 2008, 108:c194-c201. 10.1159/000118942, 18311084.
23. Ilmakunnas M, Tukiainen EM, Rouhiainen A, Rauvala H, Arola J, Nordin A, Makisalo H, Hockerstedt K, Isoniemi H. High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl 2008, 14:1517-1525. 10.1002/lt.21573, 18825712.
24. Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007, 81:67-74.
25. Pullerits R, Urbonaviciute V, Voll RE, Forsblad-D'Elia H, Carlsten H. Serum levels of HMGB1 in postmenopausal patients with rheumatoid arthritis: associations with proinflammatory cytokines, acute-phase reactants, and clinical disease characteristics. J Rheumatol 2011, 38:1523-1525.
26. Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 2013, 93:865-873. 10.1189/jlb.1212662, 23446148.
27. Pisetsky DS. The translocation of nuclear molecules during inflammation and cell death. Antioxid Redox Signal 2013